ERBB2 and breast carcinoma: Although it is approved for use in combination with capecitabine or letrozole for treating ErbB2-positive breast cancer, adjuvant lapatinib as a single agent for women with early-stage ErbB2-positive breast cancer shows marginal efficacy [10].